Teleflex (TFX)

Company Profile

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. The Company applys purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Its portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference.

Company profile

Ticker

TFX

Exchange

NYSE

Website

www.teleflex.com

CEO

Liam Kelly

Incorporated

Delaware

Location

Pennsylvania

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Resmed • West Pharmaceutical Services • Haemonetics • Hill-Rom • Integra Lifesciences ...

SEC CIK

0000096943

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

1902 Federal Road, LLC • Arrow Internacional de Chihuahua, S.A. de C.V. • Arrow Internacional de Mexico, S.A. de C.V. • Arrow International • Arrow Interventional, Inc. • Distribuidora Arrow, S.A. de C.V. • Essential Medical LLC • Hudson Respiratory Care Tecate, S. de R.L. de C.V. • ICOR AB • Inmed Manufacturing ...

IRS number

231147939

TFX stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$269.75

Low target

$250.00

High target

$293.00

Latest filings (excl ownership)

View all

Conflict minerals disclosure

26 May 23

8-K

Amendments to Articles of Incorporation or Bylaws

4 May 23

Teleflex Reports First Quarter Financial Results and Full Year 2023 Outlook

4 May 23

ARS

2022 FY

Annual report to shareholders

31 Mar 23

10 Mar 23

23 Feb 23

Teleflex Reports Fourth Quarter and Full Year 2022 Financial Results

23 Feb 23

Transcripts

View all

TFX

Earnings call transcript

2022 Q4

23 Feb 23

TFX

Earnings call transcript

2022 Q3

27 Oct 22

TFX

Earnings call transcript

2022 Q2

28 Jul 22

TFX

Earnings call transcript

2022 Q1

28 Apr 22

TFX

Earnings call transcript

2021 Q4

24 Feb 22

TFX

Earnings call transcript

2021 Q3

28 Oct 21

TFX

Earnings call transcript

2021 Q2

29 Jul 21

TFX

Earnings call transcript

2021 Q1

2 May 21

TFX

Earnings call transcript

2020 Q4

28 Feb 21

TFX

Earnings call transcript

2020 Q3

2 Nov 20

Latest ownership filings

View all

Stephen K. M.D. Klasko

Notice of proposed sale of securities

10 May 23

Financial summary

Financial statements Chart TFX financial data

Quarter (USD)	Apr 23	Dec 22	Sep 22	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	264.14 mm	264.14 mm	264.14 mm	264.14 mm	264.14 mm	264.14 mm
Cash burn (monthly)	9.30 mm	16.88 mm	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	20.75 mm	37.66 mm	n/a	n/a	n/a	n/a
Cash remaining	243.39 mm	226.48 mm	n/a	n/a	n/a	n/a
Runway (months of cash)	26.2	13.4	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from Teleflex earnings reports.

Institutional ownership, Q1 2023

TFX institutional ownership history Ownership history

97.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	470	471	-0.2%
Opened positions	56	79	-29.1%
Closed positions	57	61	-6.6%
Increased positions	183	167	+9.6%
Reduced positions	143	161	-11.2%

13F shares	Current	Prev Q	Change
Total value	11.56 tn	11.17 tn	+3.4%
Total shares	45.68 mm	45.11 mm	+1.3%
Total puts	20.40 k	82.50 k	-75.3%
Total calls	42.10 k	145.50 k	-71.1%
Total put/call ratio	0.5	0.6	-14.5%

Largest owners	Shares	Value	Change
T. Rowe Price Investment Management	8.56 mm	$2.17 tn	-0.9%
Vanguard	5.45 mm	$1.38 tn	+0.6%
BLK Blackrock	3.98 mm	$1.01 tn	+0.3%
Wellington Management	3.10 mm	$785.39 bn	+0.3%
JHG Janus Henderson	3.10 mm	$785.25 bn	+44.6%
MS Morgan Stanley	2.89 mm	$732.49 bn	+7.4%
STT State Street	2.33 mm	$589.95 bn	+2.0%
T. Rowe Price	1.83 mm	$464.52 bn	+50.1%
Geode Capital Management	971.68 k	$245.58 bn	+2.4%
Allspring Global Investments	844.50 k	$213.92 bn	+5.1%

Largest transactions	Shares	Bought/sold	Change
JHG Janus Henderson	3.10 mm	+955.93 k	+44.6%
T. Rowe Price	1.83 mm	+612.02 k	+50.1%
Norges Bank	0.00	-418.00 k	EXIT
DF Dent & Co	14.73 k	-353.45 k	-96.0%
Cooke & Bieler	312.84 k	+312.84 k	NEW
MS Morgan Stanley	2.89 mm	+200.47 k	+7.4%
Ceredex Value Advisors	226.71 k	-145.89 k	-39.2%
Clearbridge Advisors	130.03 k	+130.03 k	NEW
Arrowstreet Capital, Limited Partnership	86.90 k	-122.45 k	-58.5%
Bamco	5.90 k	-121.90 k	-95.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TFX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
9 May 23	Duncan Candace H	Common Stock	Grant	Acquire A	No	No	0	527	0.00	4,041.252
9 May 23	Duncan Candace H	Stock Option / Common Stock	Grant	Acquire A	No	No	251.99	1,076	271.14 k	1,076
9 May 23	Gretchen R Haggerty	Common Stock	Grant	Acquire A	No	No	0	527	0.00	4,105
9 May 23	Gretchen R Haggerty	Stock Option / Common Stock	Grant	Acquire A	No	No	251.99	1,076	271.14 k	1,076
9 May 23	Heinmiller John C	Common Stock	Grant	Acquire A	No	No	0	527	0.00	2,476
9 May 23	Heinmiller John C	Stock Option / Common Stock	Grant	Acquire A	No	No	251.99	1,076	271.14 k	1,076
9 May 23	Klasko Stephen K. M.D.	Common Stock	Grant	Acquire A	No	No	0	681	0.00	4,563.462
9 May 23	Klasko Stephen K. M.D.	Stock Option / Common Stock	Grant	Acquire A	No	No	251.99	1,076	271.14 k	1,076
9 May 23	Krakauer Andrew A	Common Stock	Grant	Acquire A	No	No	0	527	0.00	4,471.577
9 May 23	Krakauer Andrew A	Stock Option / Common Stock	Grant	Acquire A	No	No	251.99	1,076	271.14 k	1,076